Clinical Trials

Phase 3 trial

FESPIXON ® the 1st, large scale of RCT for a

M1/M2 macrophage regulating drug in DFUs patients

Performed in 21 medical centers

*Complete healing, defined as complete epithelialization maintained without drainage or requirement of dressings for at least 2 consecutive visits
DFUs = diabetic foot ulcers; RCT = randomized control trial; US = United States
Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.

Baseline characteristics

Baseline characteristics

*Due to previous diabetic foot ulcers
SD = standard deviation
Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.

FESPIXON ® exhibited superior and faster efficacy in the healing of DFUs within only 16 weeks

Kaplan-Meier Plot of Time to Complete Healing

CI = confidence interval; DFUs = diabetic foot ulcers; OR = odds ratio; vs = versus
Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.

FESPIXON ® demonstrated robust efficacy even in high-risk patients

Complete healing rate within 16 weeks in high-risk patients

Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.

FESPIXON ® offers robust safety profile

Fespixon offers robust safety profile

TEAEs = treatment-emergent adverse events
Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.